Is AMBS or JNJ a better dividend investment in 2026?

AMBS currently yields 20000000.00% with a 5% 5-year dividend growth rate. JNJ yields 3.36% with 5.8% growth. The better choice depends on your goal: AMBS offers higher current income.

What is the dividend yield difference between AMBS and JNJ?

AMBS has a forward dividend yield of 20000000.00% ($2.00/share annually). JNJ yields 3.36% ($4.96/share annually). The yield gap is 19999996.64 percentage points.

Home › Compare › AMBS vs JNJ

AMBS vs JNJ: Dividend Comparison 2026

AMBS yields 20000000.00% · JNJ yields 3.36%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 AMBS wins by $4.875981653489057e+49M in total portfolio value

INVESTMENT

TIME HORIZON10 years

AMBS

● Live price

20000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.875981653489057e+49M

Annual income

$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00

Full AMBS calculator →

JNJ

Johnson & Johnson

● Live price

3.36%

Share price

$147.50

Annual div

$4.96

5Y div CAGR

5.8%

Payout ratio

55%

After 10 yrs · $10,000 · DRIP

Portfolio value

$20.0K

Annual income

$827.78

Full JNJ calculator →

Portfolio growth — AMBS vs JNJ

📍 AMBS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	AMBS	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, AMBS + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

AMBS pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMBS

Annual income on $10K today (after 15% tax)

$1,700,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$285.83/yr

After 10yr DRIP, annual income (after tax)

$703.61/yr

At 15% tax rate, AMBS beats the other by $41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMBS + JNJ for your $10,000?

AMBS: 50%JNJ: 50%

100% JNJ50/50100% AMBS

Portfolio after 10yr

$2.4379908267445285e+49M

Annual income

$24,379,668,474,955,630,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

100.00%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AMBS

No analyst data

Altman Z

-19.3

Piotroski

3/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

+55.1% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMBS buys

JNJ buys

No recent congressional trades found for AMBS or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricAMBSJNJ

Forward yield	20000000.00% ✓	3.36%
Annual dividend / share	$2.00	$4.96 ✓
Payout ratio	50% ✓	55%
1-year div growth	0%	4.2% ✓
5-year div CAGR	0%	5.8% ✓
Portfolio after 10y	$4.875981653489057e+49M	$20.0K ✓
Annual income after 10y	$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓	$827.78
Total dividends collected	$4.875978515990276e+49M	$5.6K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: AMBS vs JNJ ($10,000, DRIP)

Year	AMBS Portfolio	AMBS Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$2,000,010,700	$2,000,000,000.00	$10,676	$355.77	+$2000.00M → AMBS
2	$373,835,915,712,384	$373,833,775,700,934.50	$11,407	$389.39	+$373835915.70M → AMBS
3	$65,304,953,364,964,970,000	$65,304,553,360,535,160,000.00	$12,198	$426.53	+$65304953364964.96M → AMBS
4	$10,661,728,832,755,500,000,000,000	$10,661,658,956,455,399,000,000,000.00	$13,056	$467.62	+$10661728832755499008.00M → AMBS
5	$1,626,767,783,781,495,000,000,000,000,000	$1,626,756,375,731,643,800,000,000,000,000.00	$13,987	$513.12	+$1.626767783781495e+24M → AMBS
6	$231,974,330,054,625,100,000,000,000,000,000,000	$231,972,589,413,096,470,000,000,000,000,000,000.00	$14,998	$563.56	+$2.319743300546251e+29M → AMBS
7	$30,915,106,403,922,057,000,000,000,000,000,000,000,000	$30,914,858,191,388,900,000,000,000,000,000,000,000,000.00	$16,098	$619.52	+$3.0915106403922057e+34M → AMBS
8	$3,850,507,985,839,278,000,000,000,000,000,000,000,000,000,000	$3,850,474,906,675,425,000,000,000,000,000,000,000,000,000,000.00	$17,295	$681.69	+$3.8505079858392777e+39M → AMBS
9	$448,210,261,035,314,200,000,000,000,000,000,000,000,000,000,000,000	$448,206,140,991,769,400,000,000,000,000,000,000,000,000,000,000,000.00	$18,599	$750.82	+$4.4821026103531426e+44M → AMBS
10	$48,759,816,534,890,570,000,000,000,000,000,000,000,000,000,000,000,000,000	$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00	$20,022	$827.78	+$4.875981653489057e+49M → AMBS

AMBS vs JNJ: Complete Analysis 2026

AMBS — Stock

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.

Full AMBS Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →

📬

Get this AMBS vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMBS vs SCHD AMBS vs JEPI AMBS vs O AMBS vs KO AMBS vs MAIN AMBS vs ABBV AMBS vs MRK AMBS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.